GSA Capital Partners LLP bought a new stake in Steris PLC (NYSE:STE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,211 shares of the medical equipment provider’s stock, valued at approximately $284,000.
Other large investors have also recently modified their holdings of the company. Neuberger Berman Group LLC raised its holdings in Steris by 10.8% during the third quarter. Neuberger Berman Group LLC now owns 9,083 shares of the medical equipment provider’s stock worth $803,000 after purchasing an additional 886 shares in the last quarter. California Public Employees Retirement System raised its holdings in Steris by 7.1% during the third quarter. California Public Employees Retirement System now owns 211,344 shares of the medical equipment provider’s stock worth $18,683,000 after purchasing an additional 14,062 shares in the last quarter. Zions Bancorporation acquired a new stake in Steris during the third quarter worth approximately $178,000. Vident Investment Advisory LLC acquired a new position in shares of Steris in the 3rd quarter valued at $952,000. Finally, Keeley Teton Advisors LLC increased its holdings in shares of Steris by 41.1% in the 3rd quarter. Keeley Teton Advisors LLC now owns 21,721 shares of the medical equipment provider’s stock valued at $1,920,000 after acquiring an additional 6,332 shares during the period. 89.44% of the stock is currently owned by hedge funds and other institutional investors.
In other Steris news, insider Michael J. Tokich sold 11,000 shares of the business’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $92.00, for a total transaction of $1,012,000.00. Following the sale, the insider now directly owns 58,588 shares in the company, valued at approximately $5,390,096. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP John Adam Zangerle sold 3,650 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total transaction of $321,200.00. The disclosure for this sale can be found here. 2.55% of the stock is currently owned by insiders.
Steris (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share for the quarter, missing analysts’ consensus estimates of $0.95 by ($0.01). Steris had a net margin of 5.59% and a return on equity of 11.49%. The firm had revenue of $634.20 million during the quarter, compared to analysts’ expectations of $629.02 million. During the same quarter last year, the business earned $0.89 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. equities analysts anticipate that Steris PLC will post 4.06 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, December 20th. Shareholders of record on Wednesday, November 22nd were given a dividend of $0.31 per share. The ex-dividend date was Tuesday, November 21st. This represents a $1.24 annualized dividend and a dividend yield of 1.35%. Steris’s payout ratio is currently 73.81%.
A number of equities analysts have recently commented on the stock. TD Securities lifted their target price on shares of Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Raymond James Financial lifted their target price on shares of Steris from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, October 16th. Zacks Investment Research upgraded shares of Steris from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, KeyCorp reiterated an “overweight” rating and issued a $101.00 price objective (up from $91.00) on shares of Steris in a research report on Thursday, November 2nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $79.50.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.